Leaders in Supply & Demand Side Intelligence

Forgot your login?

[X]

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.

E-Mail:
Also, what is 66 + 4?

China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies

Premium Article
China mAbs 0621
Attachment Included

BEIJING, CHINA--Researched by Industrial Info Resources (Sugar Land, Texas)--According to the quarterly financial reports from China's listed pharmaceutical companies, Jiangsu Hengrui Medicine Company Limited has 40 new drugs under development, the most of any Chinese firm, followed by Jiangsu Chia Tai-Tianqing Pharmaceutical Company Limited with 34, and Shanghai Junshi Biosciences Company Limited with 20.

Read the Complete Article
Details on this Article:
Industry Segment: Pharmaceutical & Biotech
Word Count: 150 Words
Attachment: China mAbs 0621
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles
Premium News Article
  Key Players in China's CDMO Pharma-Bio Market Push Forward
Premium News Article
  China Authorizes Five Companies to Make COVID-19 Vaccines
Premium News Article
  China's Pharma Companies Face Fiscal Challenges for R&D Projects
Premium News Article
  Real Estate Developers Pour $34 Billion into Global Life Science Building D...
Premium News Article
  China's Pharma Market Could See New Growth Wave as India's Plants Close

PREMIUM ARTICLE

This article is available for Premium Members only.

Subscribe Now! All Fields are Required...


Pricing Help?

All Members Receive the Following Resources:

  • Industry News Digest
  • Upcoming Webinars
  • On-Demand Webinars
  • The NavigatIIR Newsletter
  • Daily Industry News Blog
  • Economic Indicators